receptor associated protein of the synapseGenealiases: CMS11 · CMS4C · FADS · RAPSYN · RNF205
Q-omics provides the consensus-scored RAPSN profile across patient tissues and cancer cell-line models. RAPSN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAPSN is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, RAPSN RNA expression shows 12,749 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LIHC, and TGCT as cancer lineages where RAPSN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPSN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPSN survival associations across molecular data types. RAPSN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPSN RNA expression–survival associations across cancer types. High RAPSN expression shows unfavorable associations in LGG, KIRC and THCA, but favorable associations in UVM, ESCA and READ. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAPSN RNA expression.
This table summarizes RAPSN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RAPSN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPSN shows lower tumor expression in LUAD, KIRC and READ and higher tumor expression in LIHC, BLCA and CHOL. The LIHC box plot shows higher RAPSN RNA expression in tumor versus normal tissue (log2 FC = +0.240, t-test p < 0.001).
This table shows molecular features associated with RAPSN in patient tissues and cancer cell lines. In patient samples, RAPSN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RAPSN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
